Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint as SINTBILO® (Tafolecimab Injection) Shows Potent Lipid-Lowering Efficacy for Hyperlipidemia

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4WSINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) after 12-week treatment,…